In fact, it's the first blood glucose monitoring system that doesn't require patients to prick their finger.
There's good characteristics to the new device, and investors are realizing just how competitive it can be against DexCom's offering, Cramer reasoned.
MediCare and the FDA are really going to like the new device, said Cramer, who also manages the Action Alerts PLUS charitable trust portfolio.
A confirmation email has been sent to the address provided during registration.
Please click on the appropriate link to confirm your email address.